Cancer ‘precision medicine’

Cancer ‘precision medicine’

This refers to the development of individualised cancer care plans, partly on the basis of molecular abnormalities in a tumour. Germline and somatic mutations may be taken into consideration, with the aim of tailoring treatments and targeting cancer cells precisely . With NGS, analysis of a single sample of tumour tissue for multiple known mutations that may predict treatment response is possible. In addition, many assays can detect mutations a ff ecting as few as 5% of neoplas - tic cells. Other techniques may be used at the same time to detect abnormalities in the proteome (protein), transcriptome (mRNA), metabolome (metabolites) or epigenome, sometimes referred to as ‘omics’ assays. Such plans may , inevitably , be ver y complex (see Chapter 12 ). Cancer ‘precision medicine’

This refers to the development of individualised cancer care plans, partly on the basis of molecular abnormalities in a tumour. Germline and somatic mutations may be taken into consideration, with the aim of tailoring treatments and targeting cancer cells precisely . With NGS, analysis of a single sample of tumour tissue for multiple known mutations that may predict treatment response is possible. In addition, many assays can detect mutations a ff ecting as few as 5% of neoplas - tic cells. Other techniques may be used at the same time to detect abnormalities in the proteome (protein), transcriptome (mRNA), metabolome (metabolites) or epigenome, sometimes referred to as ‘omics’ assays. Such plans may , inevitably , be ver y complex (see Chapter 12 ). Cancer ‘precision medicine’

This refers to the development of individualised cancer care plans, partly on the basis of molecular abnormalities in a tumour. Germline and somatic mutations may be taken into consideration, with the aim of tailoring treatments and targeting cancer cells precisely . With NGS, analysis of a single sample of tumour tissue for multiple known mutations that may predict treatment response is possible. In addition, many assays can detect mutations a ff ecting as few as 5% of neoplas - tic cells. Other techniques may be used at the same time to detect abnormalities in the proteome (protein), transcriptome (mRNA), metabolome (metabolites) or epigenome, sometimes referred to as ‘omics’ assays. Such plans may , inevitably , be ver y complex (see Chapter 12 ).